Drug Trial Radar · NCT07821762
A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
63
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jan 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- Sep 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to learn whether empasiprubart, when given in addition to intravenous immunoglobulin (IVIg), helps adults with Guillain-Barré syndrome (GBS) recover and whether it is safe. About 63 participants will be assigned by chance to receive either empasiprubart or placebo by intravenous infusion; all participants will also receive IVIg. The study includes screening for up to 72 hours, study treatment for the first two weeks, and follow-up through Week 67 (15 months after the last dose of study treatment). Participation lasts up to 67 weeks.
Conditions
- Guillain-Barré Syndrome (GBS)
Interventions
Empasiprubart IVBiological
Intravenous infusion of Empasiprubart
Empasiprubart Placebo IVOther
Intravenous infusion of Placebo
Intravenous immunoglobulin (IVIg)Biological
Intravenous infusion of IVIg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants With a Guillain-Barré Syndrome Disability Scale (GBS-DS) Score ≤2 at Week 4Time frame: at week 4
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.